Rohto Pharmaceutical Co Ltd (JP:4527)
:4527
Want to see JP:4527 full AI Analyst Report?
Top Page
Rohto Pharmaceutical Co
(4527)
Select Model
Select Model
Rating:72Outperform
Price Target:
¥2,683.00
▲(4.80% Upside)
Action:Reiterated
Date:05/15/26
Overall score is driven primarily by strong fundamentals (growth with solid profitability and manageable leverage), supported by reasonable valuation and a modest dividend yield. The main drag is weaker technical momentum (negative MACD, sub-50 RSI, and price below the 100/200-day averages).
Positive Factors
Multi-year Revenue Growth
Consistent multi-year revenue growth (181.1B to 343.7B, 2021–2026) indicates durable demand and successful expansion of OTC, eye-care and skincare lines. Sustained top-line momentum increases scale economies, funds R&D and marketing, and supports international rollouts over years.
Negative Factors
Margin Compression Since 2024
Margin compression across gross, operating and EBITDA margins since 2024 signals rising input costs or adverse product-mix shifts. If persistent, this reduces operating leverage, constrains margin expansion opportunities and forces trade-offs between pricing, marketing and long-term brand investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year Revenue Growth
Consistent multi-year revenue growth (181.1B to 343.7B, 2021–2026) indicates durable demand and successful expansion of OTC, eye-care and skincare lines. Sustained top-line momentum increases scale economies, funds R&D and marketing, and supports international rollouts over years.
Read all positive factors
Rohto Pharmaceutical Co (4527) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥546.73B
Dividend Yield1.53%
Average Volume (3M)643.03K
Price to Earnings (P/E)15.6
Beta (1Y)0.48
Revenue Growth11.37%
EPS Growth11.35%
CountryJP
Employees7,259
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)151.24
Shares Outstanding236,178,310
10 Day Avg. Volume564,110
30 Day Avg. Volume643,026
Financial Highlights & Ratios
PEG Ratio1.40
Price to Book (P/B)1.80
Price to Sales (P/S)1.58
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)156.36
Revenue Forecast (FY)¥366.46B
Rohto Pharmaceutical Co Business Overview & Revenue Model
Company Description
Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global entity engaged in the development, manufacturing, and marketing of a diverse array of pharmaceutical goods, beauty products, and nutritional supplements. Their compreh...
How the Company Makes Money
Rohto primarily makes money by selling branded healthcare products through retail and wholesale channels, with revenue driven mainly by (1) OTC pharmaceuticals and related consumer health items (notably eye drops and other eye-care remedies) and (...
Rohto Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
79
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 322.23B | 343.73B | 308.63B | 270.84B | 238.66B | 199.65B |
| Gross Profit | 179.71B | 182.96B | 169.46B | 154.93B | 135.13B | 114.10B |
| EBITDA | 61.26B | 65.48B | 56.42B | 50.40B | 42.34B | 35.81B |
| Net Income | 34.23B | 34.25B | 31.00B | 30.94B | 26.38B | 21.13B |
Balance Sheet | ||||||
| Total Assets | 428.33B | 485.77B | 421.88B | 346.18B | 309.68B | 274.88B |
| Cash, Cash Equivalents and Short-Term Investments | 75.84B | 86.82B | 77.16B | 89.21B | 79.95B | 72.79B |
| Total Debt | 48.88B | 60.24B | 61.23B | 12.81B | 12.88B | 21.72B |
| Total Liabilities | 144.18B | 165.59B | 150.43B | 99.14B | 94.60B | 90.88B |
| Stockholders Equity | 266.74B | 301.83B | 260.10B | 246.33B | 209.57B | 178.40B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 36.29B | 27.84B | 26.27B | 22.45B | 16.98B |
| Operating Cash Flow | 0.00 | 47.79B | 36.92B | 34.24B | 30.92B | 27.25B |
| Investing Cash Flow | 0.00 | -29.78B | -57.55B | -16.32B | -13.18B | -16.41B |
| Financing Cash Flow | 0.00 | -11.85B | 3.70B | -13.78B | -16.20B | 3.47B |
Rohto Pharmaceutical Co Technical Analysis
Neutral
2560.00
Price Trends
2394.10
Negative
2407.98
Negative
2449.79
Negative
Market Momentum
-21.11
Positive
48.88
Neutral
56.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4527, the sentiment is Neutral. The current price of 2560 is above the 20-day moving average (MA) of 2362.07, above the 50-day MA of 2394.10, and above the 200-day MA of 2449.79, indicating a bearish trend. The MACD of -21.11 indicates Positive momentum. The RSI at 48.88 is Neutral, neither overbought nor oversold. The STOCH value of 56.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4527.
Rohto Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥546.73B | 15.55 | 12.66% | 1.53% | 11.37% | 11.35% | |
69 Neutral | ¥285.25B | 27.85 | 2.72% | 2.61% | 1.63% | 74.87% | |
65 Neutral | ¥411.16B | 135.15 | 5.37% | 1.95% | 3.14% | -71.37% | |
64 Neutral | ¥2.82T | 23.07 | 11.50% | 2.41% | 3.60% | 13.80% | |
64 Neutral | ¥460.70B | 17.14 | 9.09% | 1.73% | 3.10% | 27.99% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
52 Neutral | ¥998.72B | -27.93 | ― | 2.11% | 0.45% | -836.50% |
* Consumer Defensive Sector Average
JP:4527
Rohto Pharmaceutical Co
2,355.00
357.46
17.89%
JP:4452
Kao
6,241.00
-99.09
-1.56%
JP:4967
Kobayashi Pharmaceutical Co
5,544.00
156.06
2.90%
JP:4922
Kose
5,000.00
-559.83
-10.07%
JP:4912
Lion
1,697.50
209.88
14.11%
JP:4911
Shiseido Company,Limited
2,500.00
-49.16
-1.93%
Rohto Pharmaceutical Co Corporate Events
Rohto Board Rejects Shareholder Bid to Oust Veteran Director Kunio Yamada
May 13, 2026
Rohto Pharmaceutical’s board has formally opposed two shareholder proposals submitted ahead of its June 24, 2026 ordinary general meeting, including one calling for the dismissal of director and former president Kunio Yamada. The board argue...
Rohto Pharmaceutical Lifts Dividend Forecast on Stronger Earnings Outlook
May 13, 2026
Rohto Pharmaceutical Co. has revised its dividend plan for the fiscal year ending March 31, 2026, raising the forecast year-end dividend from ¥23 to ¥25 per share and lifting the total annual dividend from ¥44 to ¥46. This foll...
Rohto Pharmaceutical Lifts Earnings, Strengthens Balance Sheet and Raises Dividend
May 13, 2026
Rohto Pharmaceutical reported consolidated net sales of ¥343.7 billion for the year ended March 31, 2026, up 11.4% year on year, with operating income rising 7.5% to ¥41.1 billion and profit attributable to owners of parent climbing 11.0...
Rohto Faces Activist Shareholder Proposals Ahead of June Shareholders’ Meeting
Apr 30, 2026
Rohto Pharmaceutical Co., Ltd. disclosed that it has received two shareholder proposals ahead of its 90th Ordinary General Meeting of Shareholders scheduled for June 24, 2026. The proposals were submitted by AVI Japan Opportunity Trust PLC and LON...
Rohto Pharmaceutical Launches ¥3 Billion Share Buyback to Boost Capital Efficiency
Mar 26, 2026
Rohto Pharmaceutical has approved a share repurchase program of up to 1.5 million shares, equivalent to 0.66% of its outstanding stock excluding treasury shares, with a maximum outlay of ¥3 billion. The buyback, to be executed via market purc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.